Chronicles of a Biosimilar Production Facility 

Biologic restorative items created through rDNA innovation as recombinant protein-based solutions that have been in clinical use since the mid-1980s as unique biopharmaceuticals have extraordinarily added to the treatment of extreme metabolic and degenerative infections. The late close of the information assurance or licenses for the greater part of them made open doors for the advancement of duplicate adaptations of unique biopharmaceuticals with comparative biologic movement (named biosimilars). Generation of these new items is relied upon to take care of overall demand, advance market rivalry, keep up the impetuses for development, and maintain the human services frameworks.

  • Analysis of the Biosimilar Development Pipeline
  • Physicochemical Biosimilar Comparability Studies
  • Biosuperior Development Strategies

Related Conference of Chronicles of a Biosimilar Production Facility 

November 09-11, 2017

4th European Biopharma Congress

Vienna, Austria
August 20-22, 2018

9th Asian Biologics and Biosimilars Congress

Tokyo, Japan

Chronicles of a Biosimilar Production Facility  Conference Speakers

Recommended Sessions

Related Journals

Are you interested in